So, with ICOS on its way out, it’s time to talk about the up-and-comers. While it’s not fun to lose the flagship for the region’s biotech industry, there are a number of other companies with the potential to grow big: In Bothell, those include Nastech, Sonus and Seattle Genetics.
Seattle Genetics is lately in the news because of its $860-million-plus drug licensing deal with Genentech. In today’s Herald, we took a closer look at what that deal means and where the company is going, http://www.heraldnet.com/stories/07/01/29/100bus_seagen001.cfm.
Here’s my question, and I’m happy to take input on this one: Who’s likely to be the next big firm out of Bothell or Seattle? With 500-plus employees and a market cap of more than $1 billion, ZymoGenetics seems to have the lead, but there certainly are others with the potential to do big things.
Talk to us
> Give us your news tips.
> Send us a letter to the editor.
> More Herald contact information.